"Eventually traders will sell out & this stock will then have a big run based on its fundamentals."
If we've learnt anything in the last few days it's that Australian investing is almost all chart based. Traders with the instincts of sharks, the attention spans of goldfish, who don't know/care if they're trading diamonds or dead babies, and who don't need fundamentals.
And anyway the fundamental fundamental is that management are too busy feeding themselves to develop a business plan that might see BTA become a blue chip stock. Instead of value adding our intellectual property, their idea of good management is to give over control to a partner who develops, produces and sells the drugs, and pays just enough royalty to fund management lifestyles.
Where's the ongoing research? What's the fifty year plan?
BTA has a cure for the common cold. The pharm. industry doesn't want it to succeed because of the money being made treating cold symptoms. A pharm. will only partner BTA to sabotage the cure.
Relenza royalties should be used by BTA to trial, manufacture, and market the cure independently. That's a plan.
Poorly performing management must be culled.
- Forums
- ASX - By Stock
- BTA
- peter cook is a financial wizard
peter cook is a financial wizard, page-22
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online